Treatment Resistant Depression
214
42
61
82
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Published Results
38 trials with published results (18%)
Research Maturity
82 completed trials (38% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
5.6%
12 terminated out of 214 trials
87.2%
+0.7% vs benchmark
16%
34 trials in Phase 3/4
46%
38 of 82 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 82 completed trials
Clinical Trials (214)
DBS for TRD With the Medtronic Summit RC+S
DBS for TRD With the Medtronic Percept PC
DBS for Depression
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The MIND1 Trial
Exercise to Augment TMS in Those With Treatment Resistant Depression
Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)
Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
Psilocybin for Treatment-Resistant Depression
Predictors of Intravenous Ketamine Response in TRD
Antidepressant Effects of Nitrous Oxide
Ketamine Augmentation of ECT in Treatment-Resistant Depression
Intensive Accelerated iTBS for the Treatment-Resistant Depression
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression
Mindfulness Engaged Neurostimulation for Depression (MEND II)
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)